Hemopexin preparations

By optimizing the ingredients and conditions in the liquid preparation, including the concentration of heme-binding protein, buffer solution and sodium chloride concentration, and the use of nonionic surfactants, the stability of heme-binding protein is improved, solving its stability in liquid preparations, ensuring its effectiveness and storage stability at high temperatures.

JP7626369B2Active Publication Date: 2025-02-07ツェットエルベー ベーリング アクチエンゲゼルシャフト
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020507081
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-27
Filing Date
2018-08-08
Publication Date
2025-02-07
Estimated Expiration
2038-08-08

AI Technical Summary

Technical Problem

In the prior art, purified hemopexin liquid preparations have poor stability, resulting in limited application in the treatment of hemolysis-related conditions.

Method used

Polysorbate 80 (Polysorbate 80) is combined with the nonionic surfactant polysorbate 80 (Polysorbate 80) to improve the stability of the heme-binding protein by preparing a stable liquid formulation containing at least 50 mg/mL of heme-binding protein, 15 mM phosphate buffer, 50 mM sodium chloride and pH 5.8-8.

Benefits of technology

It achieved stability of heme-binding protein at least 75% of monomers at 37°C, extended the storage period of the formulation, and maintained its high affinity binding ability to heme, and was suitable for the treatment of hemolysis-related conditions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention generally relates to a stable liquid formulation of purified hemopexin, comprising: (a) a hemopexin content of at least 50 mg / mL; (b) a phosphate buffer of at least 15 mM; (c) a pH of 5.8 to 8; and (d) at least 50 mM sodium chloride, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Protein purification methods

    JP2015532301A

  • Stabilized liquid polypeptide-containing pharmaceutical composition

    JP2003510368A

  • growth hormone solution

    JP2007532515A

  • Pharmaceutical preparations

    JP2015509526A

  • Stable pharmaceutical composition of TNFR:FC fusion protein

    JP2015535237A